Nova Eye Medical Ltd · ASX:EYE
Nova Eye Medical — H1 FY2022 Earnings Presentation
19 slides from Nova Eye Medical's earnings presentation, Feb 17, 2022
Slide 1: Results Presentation for the Six Months Ended 31 December 2021
Nova Eye Medical Limited (ASX:EYE) Results Presentation for the Six Months Ended 31 December 2021 17 February 2022
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Nova Eye Medical Limited (ASX: EYE). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability of any st
Slide 3: ASX: EYE Business Snapshot
ASX: Eye Business Snapshot Nova Eye Medical Limited (ASX:EYE) comprises two business units, Glaucoma and AMD/2RT® – these segments address the leading causes of blindness in the developed world. Nova Eye Medical, Glaucoma AlphaRET, AMD Develop, market and sell comprehensive portfolio Strategy Progre
Slide 4: Glaucoma Market Strong Global Growth Theme
Glaucoma Market Strong Global Growth Theme Glaucoma is the leading cause of irreversible blindness and the second leading cause of blindness worldwide. The aging global population is driving increased glaucoma prevalence and provides strong platform for growth. Advancements in diagnostic and imaging
Slide 5: Nova Eye's Market Presence
Nova Eye’s Market Presence LEGEND Population with Glaucoma Glaucoma Surgical Device Market 5.0 million people1 US$101 million currently growing at 21%1 5.1 million people1 $455 million Nova Eye Germany based in currently growing at 10%1 Berlin with sales team selling direct 11.4 million people1 to G
Slide 6: Glaucoma Technology Portfolio and Pipeline
Glaucoma Technology Portfolio and Pipeline Comprehensive portfolio of glaucoma technologies spanning the entire glaucoma treatment algorithm, underpinned by a robust R&D and IP pipeline. STAGE OF GLAUCOMA PROGRAM STATUS MILD MODERATE SEVERE COMPLEX GLAUCOMA GLAUCOMA GLAUCOMA GLAUCOMA COMMERCIAL Cana
Slide 7: The proprietary iTrack™
The proprietary iTrack™ is a manually deployed microcatheter used to perform canaloplasty, a breakthrough surgical procedure that can be performed via either an ab-interno surgical technique (akin to “keyhole” surgery) i.e., MIGS, or via an ab-externo 10+ years surgical technique (major eye surgery)
Slide 8: The next generation iTrack™ Advance
The next generation iTrack™ Advance is an injector deployed microcatheter. It takes the established effectiveness, accuracy and reliability of the original iTrack™ microcatheter and combines it with an ergonomic, easy-to-use handheld injector designed for all ophthalmic surgery and specialist settin
Slide 9: Molteno3® Glaucoma Drainage Device
Implanted in thousands of patients worldwide for more than 30 years, the Molteno3® Glaucoma Drainage Device has been clinically 30+ years validated to deliver consistent, long-term of surgical use reduction in intraocular pressure (IOP) in cases of severe or complex glaucoma. Indication Glaucoma Dra
Slide 10: iTrack™ Advance Development Milestones
iTrack™ Advance Development Milestones ✓ PRODUCTION UNITS ✓ CE MARK ✓ EUROPEAN PRE-LAUNCH ACTIVITIES EUROPEAN LAUNCH US FDA (510K) MARKETING CLEARANCE USA LAUNCH MAGIC STUDY TO SUPPORT EDUCATIONAL EFFORTS – NOT REQUIRED FOR USA LAUNCH nova-eye.com | 10
Slide 11: iTrack™ Advance Sales Growth Strategy
iTrack™ Advance Sales Growth Strategy 1 The new iTrack™ Advance device has broad market appeal. The current iTrack™ device is principally sold to glaucoma surgeons only. 2 In the USA there are approximately 1,2001 glaucoma surgeons. 3 The iTrack™ Advance will allow access to comprehensive ophthalmol
Slide 12: European Market Update
European Market Update Financial Performance: solid growth in German market as a result of establishment of sales team and its expansion, with sales revenue up 26% during the period compared to the PCP. Half year to Half year to December 2020 December 2021 Growth (US $’000’s) (US $’000’s) Revenue 97
Slide 13: USA Market Update
USA Market Update Financial Performance: sales revenue down 10% compared to the PCP, due to increased levels of competition. Despite these challenges, new surgeon interest in canaloplasty provides a strong platform for growth for the new iTrack™ Advance canaloplasty device. Half year to Half year to
Slide 14: H1FY22 Glaucoma Operating Result
H1FY22 Glaucoma Operating Result Improved EBITDA-level operating result. A $'000's US $'000’s¹ H1FY21 H1FY22 GROWTH H1FY21 H1FY22 GROWTH Sales 6,423 6,488 1.0% 4,677 4,752 1.6% COGS (2,425) (2,660) (1,766) (1,948) Gross Margin 3,998 3,828 2,911 2,804 Gross Margin 62% 59% Operating expenditure (4,971
Slide 15: 2RT® is a proprietary, world-first nanosecond laser therapy
• Age-related macular degeneration (AMD) is the leading cause of blindness 2RT® is a proprietary, world-first in industrialized countries. nanosecond laser therapy to • While there have been major advances in the treatment of AMD in its late stages treat intermediate AMD (iAMD). (referred to as Wet
Slide 16: 2RT® Development Milestones
2RT® Development Milestones Our current strategy for 2RT® is to undertake a multi-center study, preferably in the USA, to gain FDA clearance for the treatment of intermediate AMD. ✓ PRE-CLINCAL WORK • Successfully completed Investigational Device Exemption (IDE) application with ✓ PILOT CLINICAL STU
Slide 17: Financials and Corporate Snapshot
ASX: EYE Financials and Corporate Snapshot Nova Eye Medical Limited Exchange Australian Securities Exchange Ticker EYE Management + Board Ownership 7% Shares on Issue 146 million Revenues (6 months 31 December 2021) A$6.5 million US$4.8 million1 Net Tangible Assets (at 31 December 2021) A$34.1 milli
Slide 18: Nova Eye Group Outlook
Nova Eye Group Outlook Europe: execute European launch of new iTrack™ Advance 1 canaloplasty device, commencing Q3 FY2022 USA: complete iTrack™ Advance 510(k) regulatory 2 submission to the USA Food and Drug Administration (FDA) to facilitate product launch later in 2022. China: support distribution
Slide 19: Tom Spurling, Mark Flynn, Kate Hunt
Tom Spurling Mark Flynn Kate Hunt Managing Director Investor Relations Head of Marketing M: +61 417 818 658 M: +61 416 068 733 M: +61 404 080 679 E: tspurling@nova-eye.com E: mflynn@nova-eye.com E: khunt@nova-eye.com